We performed a systematic review and meta‐analysis of randomized controlled trials to
assess the efficacy and safety of the novel, ultra‐rapid‐acting insulins aspart and lispro in …

Aims To summarize all relevant randomized controlled trials (RCTs) and provide precise
effect estimates of glycaemic efficacy/safety of faster‐acting insulin aspart administered by …

Background Faster-acting insulin aspart (faster aspart) is considered safe for use during
pregnancy and breastfeeding but has not been evaluated in this population. We aimed to …

Objectives: Reaching optimal postprandial glucose dynamics is a daily challenge for people
with type 1 diabetes (T1D). This study aimed to analyze the postprandial hyperglycemic …

The first insulin preparation injected in humans in 1922 was short-acting, extracted from
animal pancreas, contaminated by impurities. Ever since the insulin extracted from animal …

Ultra-rapid-acting insulin analogs (URAA) are a further development and refinement of rapid-
acting insulin analogs. Because of their adapted formulation, URAA provide an even faster …

Background: The GoBolus study investigated the real-world effectiveness of faster aspart in
patients with type 1 diabetes (T1D) using intermittent-scanning continuous glucose …

Introduction: This study aimed to compare efficacy and safety of ultra-rapid-acting insulin
analogs (URAIs; faster aspart [FAsp], ultra-rapid lispro [URLi], and technosphere insulin [TI]) …

Introduction This study investigated glycaemic control in individuals with type 1 (T1D) or type
2 diabetes (T2D) 6 months after initiating fast-acting insulin aspart (faster aspart) in a real …

Aims: The present study aimed to compare the pregnancy outcomes, efficacy, and safety of
faster aspart with insulin aspart among Indian women with gestational diabetes …